The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evidence supporting a link between Glucagon-Like Peptide-1 receptor agonists (GLP-1) and suicidal or self-injurious thoughts and behaviors.  The assessment comes following reports of suicidal thoughts or actions. The FDA also conducted a review of GLP-1 RAs. The FDA released an update stating that its preliminary review did not show definitive evidence that the drugs cause suicidal thoughts or actions. GLP-1 receptor agonists, including dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide, are commonly prescribed for treating type 2 diabetes and, under specific conditions, for managing weight in obese or overweight adults. The review was initiated ...